Investing to Support the Growth of our Customers - Eric Chesnel, Commercial & Licensing Director, Unither Pharmaceuticals

Strategic Shifts and Market Megatrends in Sterile Manufacturing and Biologics - Greg Behar, CEO Recipharm

CordenPharma Invests in Endto-End CDMO Supply Expansions Across Six Technology Platforms - Dr. Stephan Haitz, Chief Commercial Officer, CordenPharma

Investing in the Future: Strategic CDMO Growth in a Dynamic Market - Tim Roberts, Chief Commercial Officer, PCI Pharma Services

Lonza’s Continued Investments in Growth and Frontier Technologies to Meet the Needs of Drug Developers - Jean-Christophe Hyvert, President of Biologics, Lonza

Price revision in manufacturing agreements: Managing the issues from a legal perspective

The Rise of a New Drug Delivery System Adapted to Children and Vulnerable Patients

BSP: A Strong Leadership Position as Contract Manufacturer of ADC Products - Aldo Braca, BSP CEO

A Vision for the Future of Sterile Pharmaceutical Forms - Alexandre Bastit, CEO Pharmaceutical and API Business Unit at Fareva

Listen and Respond: Vetter’s Approach to Sustainable Growth - Thomas Otto and Peter Soelkner, Managing Directors, Vetter

The Market for Parenteral Dosage Forms

The Outstanding Future of Oncology Therapies

Termination and transfer clauses in Manufacturing and Supply Agreements (MSA)

Conquering The Latest Demand - Tom Ross, President and CEO, Grand River Aseptic Manufacturing

CDMO: Opportunities and challenges

Why 2024 could be a buyers’ market in Biopharma

Cell and gene therapies: between hopes and uncertainty

Strong Turbulence in European MedTech

The weight-loss drug market is shaking up the global CDMO landscape

M&A = 2023, Year of the Rebound

Towards Record Medicine Spending in 2028

The development contract: The main legal reflexes

CDMOs Early-Stage Development Strategies

What role for Europe in innovation?

CDMOs: Financial performance H1 2023

EU Commission’s proposed changes to marketing authorisation procedures

Big pharma’s new life without Covid-19 products

Biotech industry: between challenges and optimism

Building a new framework for European pharmaceutical legislation

Artificial intelligence in pharmaceutical development and manufacturing

What potential for biosimilars in healthcare systems?

Medicines: Headed for the Great Shortage?

The Intellectual Property clause in pharmaceutical subcontracting agreements

To repackage or not? Latest CJEU rulings provide guidance for parallel traders of medicines

Protection expiry in Europe: facts and figures

BIO CDMOs: Time for big investments

Nanothechnology in the healthcare

CDMO CEOs: Visions and strategies for 2022 and after

CLINICAL TRIALS ON MEDICINAL PRODUCTS: Overview of the new legal regimes

Boosting the availability of medicines in Europe